MTD METTLER TOLEDO INTERNATIONAL INC/
Laboratory Analytical Instruments · NYSE · SEC CIK 1037646 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.5%
TTM net income YoY11.8%
TTM EPS YoY15.0%
Revenue 3-yr CAGR2.4%
Net income 3-yr CAGR5.6%
Margins
Gross margin60.4%
Operating margin—
Net margin22.2%
FCF margin20.7%
EBITDA margin—
Returns
ROE—
ROA25.9%
ROIC (approx.)—
Asset turnover1.16x
Leverage & solvency
Liabilities / assets97.9%
Debt / equity26.06x
Current ratio1.10x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.05x
Accruals ratio-1.4%
Payout ratio—
Capex / revenue2.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $4.03B | $3.87B |
| Gross profit | $2.39B | $2.33B |
| R&D expense | $199.37M | $189.36M |
| SG&A expense | $998.31M | $936.30M |
| Interest expense | $68.52M | $74.63M |
| Pretax income | $1.05B | $1.04B |
| Income tax | $179.72M | $174.08M |
| Net income | $869.19M | $863.14M |
| EPS (basic) | 42.17 | 40.67 |
| EPS (diluted) | 42.05 | 40.48 |
| Weighted avg. shares (diluted) | 20.67M | 21.32M |
| Balance sheet | ||
| Cash & equivalents | $66.89M | $59.36M |
| Receivables | $778.24M | $687.11M |
| Inventory | $387.23M | $342.27M |
| Current assets | $1.36B | $1.19B |
| PP&E, net | $845.64M | $770.28M |
| Goodwill | $739.23M | $668.91M |
| Intangibles | $278.91M | $257.14M |
| Total assets | $3.71B | $3.24B |
| Current liabilities | $1.20B | $1.17B |
| Short-term debt | $63.93M | $182.62M |
| Long-term debt | $2.09B | $1.83B |
| Total debt | $2.15B | $2.01B |
| Total liabilities | $3.74B | $3.37B |
| Shareholders' equity | -$23.64M | -$126.89M |
| Net debt | $2.09B | $1.95B |
| Shares outstanding | 22.14M | 20.95M |
| Cash flow statement | ||
| Operating cash flow | $955.77M | $968.35M |
| Capital expenditure | $107.12M | $103.90M |
| Free cash flow | $848.65M | $864.45M |
| Investing cash flow | -$193.87M | -$119.46M |
| Financing cash flow | -$755.17M | -$855.98M |
| Depreciation & amortization | $51.14M | $50.35M |
| Stock-based compensation | $22.51M | $19.98M |
| Share buybacks | $800.00M | $850.00M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.